Formulary Search Results for: CALCIUM AND VITAMIN D
9.6.4 Vitamin D - View Category
Restrictions:
These formulations of calcium and vitamin D are restricted to use when Preferred List formulations are not tolerated.
Prescribing Notes:
Calcium and vitamin D tablets, chewable tablets and effervescent tablets are the preferred formulations (see Preferred List).
Please note: Calcium and vitamin D preparations may vary in strength, dosage and frequency
9.6.4 Vitamin D - View Category
Prescribing Notes:
The current preferred calcium and vitamin D preparations in Acute Services and Primary Care are
- Accrete D3 One A Day chewable tablets (once daily) is first-line preparation
- Accrete D3 film-coated tablets (twice daily) is second-line preparation for patients who do not tolerate the first-line preparation. Not suitable for patients with peanut or soybean allergy, and patients requiring a gelatin free preparation.
- Adcal D3 Dissolve effervescent tablets (twice daily) preparation of choice for patients with swallowing difficulties or who have enteral tubes.
- Adcal D3 chewable tablets are available for oncology patients to reflect oncology protocols. Not suitable for patients with peanut or soybean allergy, and patients requiring a gelatin free preparation.
Please note: Calcium and vitamin D preparations may vary in strength, dosage and frequency.
9.6.4 Vitamin D - View Category
Restrictions:
Excludes Fultium D3 3,200 unit strength. Invita D3 oral ampoules are restricted to use only when other oral vitamin D preparations are not suitable.
Prescribing Notes:
The preferred preparation in NHSGGC in Stexerol D3 1000 IU.
For NHSGGC guidance on when to measure vitamin D levels and the subsequent management of vitamin D deficiency and insufficiency click here.
Vitamin D supplementation usually falls into two broad categories, low dose supplementation and high dose supplementation. Low dose is considered to be doses of 1,000 units daily or less and is used most often for supplementation in insufficiency states. High dose vitamin D is considered to be doses in excess of 20,000 units per week. High dose vitamin D is more likely to be used in deficiency states leading to morbidity.
12.2.1 Drugs used in nasal allergy - View Category
11.6.4 Carbonic anhydrase inhibitors and systemic drugs - View Category
11.6.6 Combination preparations - View Category
Restrictions:
Restricted to specialist initiation. Preservative-free preparations are restricted to patients in whom a combination of these two agents is appropriate and who have proven sensitivity to benzalkonium chloride.
10.1.1 Non-steroidal anti-inflammatory drugs - View Category
10.1.1 Non-steroidal anti-inflammatory drugs - View Category
Restrictions:
Use of MR preparations is restricted. Modified-release preparations of any NSAID should be restricted to patients with early morning stiffness or compliance problems as they encourage regular/higher doses of NSAIDs and do not afford flexibility in reducing the dose.
Prescribing Notes:
In June 2013, the MHRA issued new contraindications and warnings for diclofenac following a review of the cardiovascular risk, which it states is similar to that of the selective COX-2 inhibitors. A summary of the guidance on the MHRA website is available HERE
9.1.1.2 Parenteral iron - View Category
Restrictions:
Treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis, when oral iron preparations are ineffective or cannot be used is restricted to specialist use only in adults with chronic kidney disease on dialysis.
9.1.1.2 Parenteral iron - View Category
Restrictions:
The treatment of iron deficiency anaemia (diagnosis based on laboratory tests) when oral iron preparations are ineffective or cannot be used is restricted to specialist use.
Prescribing Notes:
These preparations are more expensive than some other IV iron preparations. Use in patients on haemodialysis or use as a bolus injection was not recommended by SMC and remains non-Formulary.
For the relevant SMC advice click here